Verrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions
January 04, 2023 07:30 ET
|
Verrica Pharmaceuticals Inc.
Registration Stability Batch for VP-102 Completed and Placed on Stability Process Validation Batches Successfully Manufactured Verrica Reaffirms its Expected Q1 2023 NDA Resubmission for VP-102 ...
Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 07, 2022 16:05 ET
|
Verrica Pharmaceuticals Inc.
Reiterates expectation to resubmit NDA for VP-102 for Molluscum Contagiosum in Q1 2023 Part 1 of Phase 2 for VP-LTX-315 for Basal Cell Carcinoma on track to conclude Q1 2023 WEST CHESTER, Pa.,...
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 24th Annual Global Investment Conference
August 31, 2022 16:30 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results
August 11, 2022 07:30 ET
|
Verrica Pharmaceuticals Inc.
Verrica held Type A meeting with the FDA regarding the path forward for the resubmission and potential approval of the NDA for VP-102 for the treatment of molluscum contagiosum Verrica has begun...
Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum by Torii Pharmaceutical Co., Ltd. in Japan
August 01, 2022 07:30 ET
|
Verrica Pharmaceuticals Inc.
The Company earns $8 Million Phase 3 Milestone Payment WEST CHESTER, Pa., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics...
Verrica Announces Pricing of Public Offering of Common Stock
June 29, 2022 21:23 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., June 29, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Announces Proposed Public Offering of Common Stock
June 29, 2022 16:01 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., June 29, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical...
Verrica Pharmaceuticals Holds Type A Meeting with FDA for VP-102 for Molluscum Contagiosum
June 28, 2022 07:30 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., June 28, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Receives Complete Response Letter from the FDA for its NDA for VP-102 as a Direct Result of Deficiencies at General Reinspection of Sterling Pharmaceuticals Services, LLC
May 24, 2022 20:00 ET
|
Verrica Pharmaceuticals Inc.
Verrica has been advised that PAI (Pre-Approval Inspection) was conducted at Sterling and is not aware of any reported observations related to the PAI of VP-102 operations Review Division had advised...
Verrica Pharmaceuticals Reports First Quarter 2022 Financial Results
May 09, 2022 07:30 ET
|
Verrica Pharmaceuticals Inc.
Upcoming PDUFA date of May 24, 2022 for VP-102 NDA for the treatment of molluscum First patient dosed in Phase 2 trial of LTX-315 in basal cell carcinoma WEST CHESTER, Pa., May 09, 2022 (GLOBE...